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Abstract
Background: Allergic rhinitis (AR), allergic conjunctivitis (AC), and asthma
composing multiple phenotypes and improved understanding of these phenotypes
and their respective risk factors are needed.
Objectives: The objective of this study was to define the prevalence of AR, AC, and
asthma and their association with allergen‐specific immunoglobulin E (sIgE) sensi-
tization in a large cohort of blood donors and identify risk factors.
Methods: From the nationwide population‐based Danish Blood Donor Study,
52,976 participants completed an electronic questionnaire including AR, AC,
asthma, allergic predisposition, and childhood residence. Of these, 25,257 were
additionally tested for sIgE to inhalation allergens (Phadiatop).
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
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Results: The prevalence of sIgE sensitization, AR, AC, and asthmawas 30%, 19%, 15%,
and 9%, respectively. The youngest birth cohorts had the highest prevalence of sIgE
sensitization and symptoms of asthma, AR, and AC, and for asthma, they apparently
experienced symptoms at an earlier age. The sIgE sensitization was positively asso-
ciatedwithmale sex. The sIgE seroprevalencewas higher in participants with both AR
and AC (ARC) than in participants with either AR or AC. Allergic predisposition and
sIgE sensitization increased the risk of the diseases, while farm upbringing was asso-
ciated with reduced prevalence of ARC, however, only in sIgE sensitized participants.
Conclusion: Birth year, childhood residence, sIgE sensitization, and allergic predis-
position were associated with asthma, AR, and AC prevalence. Individuals with self‐
reported ARC represent a primarily sIgE‐positive phenotype, while those with either
AR or AC represent more diverse phenotypes.
K E YWORD S
allergic IgE sensitization, asthma, conjunctivitis, environment, rhinitis
1 | INTRODUCTION
Allergic rhino‐conjunctivitis and asthma are common chronic dis-
eases in the adult population with a prevalence of 20%–26% and
7%–11%, respectively.1–3 Prevalence of the diseases has increased
over the last 20 years,4 and they negatively affect the quality of
life5,6 and performance in school and at work.7,8 In allergic rhinitis
(AR) and allergic conjunctivitis (AC), immunoglobulin E (IgE) is a
central mediator of allergic inflammation induced by allergen
inhalation. Allergic sensitization is characterized by the presence of
allergen‐specific IgE (sIgE). The prevalence of inhalant allergen
sensitization is 19%–50% in the general population.9,10 Inhalant
allergen sensitization is not always concordant with allergic symp-
toms.11,12 Rhinitis and conjunctivitis may be either allergic or non‐
allergic.
AR, AC, and asthma are heterogonous diseases with interplay
between environmental and genetic factors, and they commonly
coexist in individuals (multimorbidity) and within families. Children
with a parental history of atopic diseases develop symptoms more
frequently and at a younger age compared with children of non‐
allergic parents.13 Obesity,14,15 smoking,16,17 and exposure to
airborne allergens and pollution18–20 are associated with AR, AC, and
asthma. Living on farms in early childhood (an environment rich in
microbial compounds21), on the other hand, has a protective effect
that persists in adulthood.2,10,22
The overall aim of this study was to describe AR, AC, asthma, and
inhalant allergen sensitization in a Danish nationwide cohort of adult
blooddonors. The specific aimswere to (1) determine theprevalenceof
AR, AC, asthma, and allergen sensitization; (2) explore associations
between birth year and AR, AC, and asthma in single disease and
multimorbidity with regards to prevalence and debut of symptoms; (3)
explore associations between allergen sensitization, and AR, AC, and
asthma; (4) assess potential risk factors for AR, AC, asthma, and
sensitization; (5) examine associations between geographical
upbringing and AR, AC, asthma, and sensitization; and (6) describe
months with symptoms of allergy and/or asthma in different
phenotypes.
Individuals must be in good overall health to be accepted as
blood donors, and we thus expected slightly lower disease prevalence
than in the general adult population, with the lowest prevalence in
the oldest donors. We hypothesized that sIgE sensitization, allergic
predisposition, age, and obesity were associated with increased risk
for AR, AC, and asthma, whereas farm upbringing and smoking would
have a protective effect. To our knowledge, this is one of the largest




Study participants consented to participate in the Danish BloodDonor
Study (DBDS), a nationwide prospective, population‐based study and
bio‐bank established in 2010.23–25 The participants are healthy adult
blood donors aged 18–67 years. Blood donors with AR and AC are
permitted to donate blood if they are asymptomatic on the day of
donationwithout taking antihistamines during the last 24 h. Asthmatic
donors are allowed to donate blood if they are asymptomatic on
inhalation treatment at the time of donation. In Denmark, individuals
with suspectedor confirmedallergy tomedication, latex, food, or insect
bites are not accepted as blood donors.
2.2 | Questionnaire and registers
From May 2015 to May 2018, a total of 52,976 consenting blood
donors completed an electronic questionnaire while donating
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blood.26 Questions regarding allergy, asthma, and place of upbringing
were based on standardized questions from the European Commu-
nity Respiratory Health Survey (ECRHS) questionnaire.27 AR was
defined as an affirmative answer to the question: “Do you have any
nasal allergies including hay fever?”, AC as an affirmative answer to
the question: “Do you have any eye allergies including hay fever?”,
and ARC as both AR and AC. Asthma was defined as an affirmative
answer to the question: “Do you have or have you ever had asthma?”.
Allergic and asthmatic participants stated their age at the time of the
first symptoms (in 5–10‐year age intervals) and months with
symptoms.
Based on questionnaire data, the study population was divided
into distinct single disease and multimorbidity groups (the coexisting
of asthma, AR, and/or AC). However, “only AR” and “only AC” were
merged for most analyses to avoid low numbers and insufficient
power in these groups. This resulted in six distinct phenotype groups:
asthma without AR and without AC; asthma with either AR or AC;
asthma with ARC; ARC without asthma; either AR or AC without
asthma; and controls (no AR, no AC, and no asthma). For distribution
of phenotypes, see Figure A1.
Body mass index (BMI) (kg/m2) was calculated from self‐reported
weight and height, and obesity was defined as BMI ≥ 30 kg/m2.28
Place of upbringing included six categories of urbanization. Smoking
behavior included current, former, and never smoker. More details
about the questionnaire and definitions are available in Appendices,
Questionnaire.
All citizens in Denmark are assigned a unique 10‐digit personal
identification number (civil registration number), which allows accu-
rate linkage between individuals and register data. Data on age, sex,
and current municipality residence were retrieved from Danish reg-
isters. Current municipality residence was divided into small (less
than 100,000 citizens) and large density populated municipality (at
least 100,000 citizens).
Current age was divided into 10‐year age strata or two age
groups (younger than 45 and 45 years or older). This upper age limit
is normally set to exclude participants with chronic obstructive pul-
monary disease, which is uncommon before the age of 45.1,2,29
2.3 | Serological testing
All blood donors included in DBDS from May 2015 to March 2017 in
the Central Denmark Region, Capital Region of Denmark, Region
Zealand, and North Denmark Region (N = 25,257) were tested for
IgE antibodies specific for the nine most common respiratory sensi-
tizers by a commercially available enzyme‐linked immunosorbent
assay (ImmunoCAP Phadiatop; Phadia) at Thermo Fisher Scientific.
The assay included the allergens: common silver birch (t3), Timothy
grass (g6), mugwort (w6), cat dander (e1), dog dander (e5), horse
dander (e3), house dust mites (Dermatophagoides pteronyssinus [d1]
and Dermatophagoides farinae [d2]), and molds (Penicillium chrys-
ogenum [m1], Cladosporium herbarum [m2], Aspergillus fumigatus [m3],
and Alternaria alternata [m6]). The test result was considered positive
if the concentration of sIgE was ≥0.35 kU/L.30
EDTA gel separated blood samples were centrifuged and stored
at −20°C prior to testing. The blood‐sampling date corresponded to
the date of the questionnaire response.
2.4 | Statistical analysis
In the following, we define the prevalence of AR, AC, and asthma as
the percentage who are currently or have a history of suffering from
these conditions based on self‐reported data.
Statistical analysis was performed in Stata/MP 16.1, RStudio 1.2,
and R 3.6.0. Results were reported as percentages with 95% confi-
dence intervals (CIs), and medians with interquartile ranges (IQRs).
Groups were compared by Mann–Whitney U test or Kruskal–Wallis
test for non‐normally distributed data, and chi‐squared test for cate-
gorical data whenever all estimated counts were >5, and a 105‐fold
MonteCarlo simulated estimate for Fisher's exact testwhenever some
estimated counts were ≤5. Predictors of risk were analyzed by multi-
variable logistic regression analysis (if two outcomes) and presented as
odds ratios (ORs) with 95% CIs, or multinomial logistic regression
analysis (if more than two outcomes) and presented as relative risk
ratios (RRRs, the ratio between two risk estimates) with 95% CIs.
The association between time of birth (10‐year birth cohorts)
and age at the time of first symptom of asthma, AR, and AC in distinct
single diseases and multimorbidity as well as in overlapping symptom
groups were presented as cumulative incidence proportion and also
analyzed by Poisson regression analysis. Participants entered the
study at the date of birth and were right censored on the date of
inclusion in the DBDS if they remained asymptomatic. Interval‐
censored outcomes were constructed for participants experiencing
symptoms of asthma, AR, and AC before inclusion. For multi-
morbidity groups, age at the time of first symptom of any of the
current multimorbidities was used. In addition, the effect of the
number of blood donations (1–10, 11–20, >20) on the association
between birth year and age at the time of first symptom of asthma,
AR, and AC were explored as a measure of survival bias. Results were
presented as hazard ratios (HRs) with 95% CIs.
We tested for interactions in the Poisson and logistic regression
models. If sex modified the effects of the exposures on the outcome,
analyses were stratified by sex; otherwise, overall pooled estimates
of the effects adjusted by sex were calculated.
The association between different Phadiatop cutoff values and
self‐reported ARC was analyzed by receiver operating characteristic
(ROC) curve.
2.5 | Ethics
The DBDS was approved by the Central Denmark Region Ethics
Committee (M‐20090237). The biobank and research database
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were approved by the Danish Data Protection Agency (P‐2019‐99).
Oral and written informed consent was obtained from all
participants.
3 | RESULTS
For demographics of the study population stratified by sex, see Ta-
ble 1. Differences between males and females were present for
allergic predisposition, current age, BMI, smoking behavior, place of
upbringing, and the distribution between allergy and asthma
phenotype groups.
3.1 | Prevalence of AR, AC, asthma, and inhalant
allergen sensitization
The overall prevalence of self‐reported AR, AC, and asthma among
52,976 blood donors was 19%, 15%, and 9%, respectively. The
prevalence of inhalant allergen sensitization among 25,257 blood
donors was 30%. Most cases of asthma (95%) were diagnosed by a
doctor, 3.5% had current asthma, and 25% of the allergic participants
reported asthma.
3.2 | Association between birth year and AR, AC,
and asthma
The prevalence of AR, AC, and asthma among participants younger
than 45 years was 20.9% (95% CI: 20.5%–21.4%), 16.8% (95% CI:
16.4%–17.2%), and 11.2% (95% CI: 10.9%–11.6%), respectively.
Comparing participants above 45 years with participants
younger than 45 years, the latter had the highest proportion of
allergic sensitization (33% vs. 24%), parental allergy (23% vs. 8%),
current smokers (14% vs. 12%), females (50% vs. 46%), and current
large municipality residence (49% vs. 24%). However, they had a
lower proportion of participants growing up on farms with livestock
(12% vs. 19%).
The cumulative incidence proportions of single diseases and
multimorbidity were highest in the youngest birth cohorts, see
Figure 1. We were not able to illustrate the cumulative incidence
proportions for “asthma and AC” due to the low number of par-
ticipants in this group. The cumulative incidence proportions of
symptoms of AR, AC, and asthma regardless of multimorbidity were
also highest in the youngest birth cohorts, se Figure A2. Stratifying
by the total number of blood donations had no major influence on
the effects of the birth year (Table S1), and the total number of
blood donations was included as a confounder further on, see Ta-
bles 2 and A1. The youngest birth cohorts had the highest risk
of experiencing “only asthma,” “asthma and ARC,” and “ARC,” see
Table 2. No associations between birth year and debut of symptoms
were seen for those with either AR or AC. The youngest birth
cohorts had also the highest risk of experiencing symptoms of
asthma, AR, and AC regardless of multimorbidity and they experi-
enced asthma symptoms at a significantly earlier age
(p = 2.48 � 10−26), see Figures A2 and S1.
3.3 | Association between inhalant allergen
sensitization and AR, AC, and asthma
The overall seroprevalence (inhalant allergen sensitization) was 30%
(34% in males and 25% in females). Participants with only AR had a
seroprevalence similar to those with only AC (female: 48% vs. 49%;
male: 67% vs. 70%), but the seroprevalence in participants with
ARC was substantially higher (female: 80%; male: 91%), see Ta-
ble A2. Participants with ARC and asthma had the highest sero-
prevalence (female: 86%; male: 95%), and the combined sensitivity
was 91%. Among participants without AR, AC, asthma, nasal‐, eye‐,
and respiratory symptoms 14% were sensitized (specificity 86%).
Changing the cut‐off value of a positive Phadiatop result31 did not
improve the overall performance of the test, see ROC curve analysis
in Figure A3.
3.4 | Risk factors for AR, AC, and asthma
Differences between phenotype groups were present for inhalant
allergen sensitization, allergic predisposition, current age, sex,
smoking, and geographical residence, see Tables A2 and A3.
The multinomial logistic regression analysis confirmed that the
inhalant allergen sensitized participants had a higher risk of having
asthma, AR, AC and ARC than non‐sensitized participants as
compared to the controls, while adjusting for parental allergy, cur-
rent municipality residence, obesity, smoking behavior, number of
blood donations, and age (RRR range: 1.8–36.2 in females and 2.9–
82.2 in males), see Table 3. Parental allergy also increased the risk
of all phenotypes (RRR range: 1.7–3.8). Age younger than 45
increased the risk of non‐allergic asthma, and obesity showed a
trend of increased risk of asthma. Conversely, current smoking
had a protective effect on ARC in male participants, see Tables 3,
S2a and S2b.
3.5 | Associations between geographical upbringing
and AR, AC, asthma, and allergen sensitization
Participants who grew up on farms with livestock had the lowest
proportions of AR, AC, and inhalant allergen sensitization compared
with the other urbanization categories, see Table A3 and A4 for
characteristics of the study population stratified by phenotype group
and inhalant allergen sensitization, respectively. Participants who
grew up in inner cities had a higher proportion of parental allergy
compared with those from farms with livestock (27% vs. 16%), and
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most of the participants from inner cities were residents in a large
density populated municipality.
The multinomial logistic regression analysis among participants
younger than 45 years showed that the protective effect of living on
a farm with livestock during childhood was only present for acquiring
ARC (with or without asthma) compared with almost all other ur-
banization categories, see Figure 2 and Table S3. No effect on non‐
allergic asthma by having either AR or AC was demonstrated. Based
TAB L E 1 Demographic of the study population stratified by sex (N = 52,976)
N (%) Male 27,235 (51.4) Female 25,741 (48.6) Comparison Total 52,976 (100)
N Median (IQR) Median (IQR) Median (IQR)
Age 52,976 41.2 (29.9–51.6) 39.3 (26.7–50.6) ** 40.3 (28.3–51.1)
BMI 52,824 25.5 (23.5–28.0) 24.4 (22.1–27.6) ** 25.0 (22.9–27.8)
N % (95% CI) % (95% CI) % (95% CI)
Current smokers 7008 13.0 (12.6–13.4) 13.7 (13.3–14.2) * 13.4 (13.1–13.7)
Former smokers 11,884 21.6 (21.1–22.1) 23.3 (22.8–23.8) ** 22.4 (22.1–22.8)
Large municipality 20,665 38.6 (38.0–39.2) 39.5 (38.9–40.0) NS 39.0 (38.6–39.4)
Obesity 7204 12.7 (12.3–13.1) 14.6 (14.2–15.0) ** 13.6 (13.3–13.9)
Parental allergy 9229 15.5 (15.1–15.9) 19.5 (19.0–20.0) ** 17.5 (17.1–17.8)
Age strata (years)
18–24 8219 12.1 (11.7–12.5) 19.1 (18.7–19.6) 15.5 (15.2–15.8)
25–34 12,395 24.1 (23.6–24.6) 22.7 (22.2–23.2) 23.4 (23.0–23.8)
35–44 11,531 22.9 (22.4–23.4) 20.6 (20.1–21.1) ** 21.8 (21.4–22.1)
45–54 12,138 23.6 (23.1–24.1) 22.1 (21.6–22.7) 22.9 (22.6–23.3)
55–67 8693 17.3 (16.9–17.8) 15.4 (15.0–15.9) 16.4 (16.1–16.7)
Place of upbringing
Farm with livestock 7764 13.9 (13.5–14.3) 15.6 (15.1–16.0) 14.7 (14.4–15.0)
Farm without livestock 1222 2.46 (2.28–2.65) 2.16 (1.99–2.35) 2.32 (2.19–2.45)
Rural area 10,075 19.0 (18.6–19.5) 19.2 (18.7–19.6) ** 19.1 (18.8–19.4)
Small town 17,333 32.8 (32.3–33.4) 32.9 (32.3–33.5) 32.8 (32.4–33.2)
Suburb 10,372 20.1 (19.6–20.5) 19.2 (18.8–19.7) 19.7 (19.3–20.0)
Inner city 6006 11.8 (11.4–12.2) 11.0 (10.6–11.4) 11.8 (11.1–11.7)
Phenotype groups
1 Controls 38,931 74.0 (73.4–74.5) 75.5 (75.0–76.0) 74.7 (74.3–75.1)
2 Asthma (no AR, no AC) 2359 4.35 (4.11–4.60) 4.72 (4.46–4.98) 4.53 (4.35–4.71)
3 Asthma and AR (no AC) 544 1.09 (0.97–1.22) 1.00 (0.88–1.13) 1.04 (0.96–1.13)
3 Asthma and AC (no AR) 120 0.22 (0.17–0.28) 0.25 (0.19–0.31) 0.23 (0.19–0.28)
4 Asthma and ARC 1685 3.46 (3.25–3.69) 2.99 (2.79–3.21) ** 3.23 (3.08–3.39)
5 ARC (no asthma) 5581 11.3 (10.9–11.7) 10.1 (9.70–10.4) 10.7 (10.4–11.0)
6 AR (no asthma, no AC) 2267 4.54 (4.30–4.79) 4.15 (3.91–4.40) 4.35 (4.18–4.53)
6 AC (no asthma, no AR) 627 1.06 (0.94–1.19) 1.35 (1.22–1.50) 1.20 (1.11–1.30)
Notes: Results are presented as percentages with corresponding 95% CI and medians with IQR. Groups were compared by Mann–Whitney U test for
non‐normally distributed data and chi‐squared test for categorical data. p‐Values were Bonferroni corrected; Obesity: BMI ≥ 30 kg/m2; Numbers 1–6
indicates the six distinct phenotype groups.
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on that, ARC and inhalant allergen sensitization were further
analyzed regardless of asthma and without age stratification. Farm
childhood only had a protective effect on ARC in inhalant allergen
sensitized participants, see Figure 3 and Table S4.
3.6 | Risk factors for inhalant allergen sensitization
The seroprevalence (inhalant allergen sensitization) was positively
associated with male sex, allergic predisposition, age younger than
45 years, and living in a large density populated municipality, see
Table A4. The seroprevalence in adulthood increased with
decreasing age at first symptoms of AR and AC in participants with
ARC.
The multivariable logistic regression analysis confirmed that
males had a higher risk of testing seropositive than females
(OR = 1.57, 95% CI: 1.49–1.67), while adjusting for parental allergy,
current municipality residence, obesity, smoking behavior, number of
blood donations, and current age, see Table 4. The analysis also
showed independent effect of parental allergy, age, smoking, and
current municipality residence. The risk of testing seropositive was
higher in participants with parental allergy compared with those
without (OR = 2.22, 95% CI: 2.08–2.39), in participants younger than
45 years compared with participants 45 years or older (OR = 1.33,
95% CI: 1.25–1.42), and in participants currently living in large
compared with small density populated municipalities (OR = 1.12,
95% CI: 1.06–1.19). However, current and former smoking had a
protective effect compared with never smoking (OR = 0.87, 95% CI:
0.80–0.95; OR = 0.85, 95% CI: 0.79–0.91, respectively).
3.7 | Seasonal allergy and asthma
Most allergic participants had intermittent symptoms, and the
months during which they usually experienced allergic symptoms
were from April to August (corresponding to the hay fever season)
with the highest proportion in June (grass pollen season in Denmark),
see Figure A4. The proportions of participants with symptoms were
generally higher in sensitized compared with non‐sensitized partici-
pants. Persistent AR and AC symptoms were more frequent in par-
ticipants with either AR or AC compared to those with ARC, as well
as in sensitized compared with non‐sensitized. Symptoms of both
allergic and non‐allergic asthma peaked during the winter; allergic
asthma also peaked in the summer.
3.8 | Missing data
The number of unanswered questions in the questionnaire was
approximately 4%.
0 10 20 30 40 50
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F I GUR E 1 Cumulative incidence proportions in single diseases and multimorbidity. Cumulative incidence proportions (and corresponding
95% confidence intervals) of self‐reported asthma, allergic rhinitis (AR), and allergic conjunctivitis (AC) by age in 10‐year birth cohorts in the
overall study population, irrespective of sex. Stratified in distinct single diseases and multimorbidity groups. In multimorbidity, groups age
refers to the age of first symptom irrespective of what disease. ARC, both AR and AC
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The study population (N = 52,976) comprised 3.4%
(N = 1780) participants with missing data in at least one of the
following variables: asthma, AR, AC, smoking, BMI, parental al-
lergy, and place of upbringing. Of these, 1468 had missing data in
one variable, 301 in two to three variables, and 11 in four to
seven of the variables. All participants had complete data on age,
sex, current municipality residence, and total number of blood
donations.
TAB L E 3 Risk factors for allergic rhino‐conjunctivitis and asthma by multinomial logistic regression analysis
Asthma (no AR, no AC)
Asthma, and either
AR or AC Asthma and ARC ARC (no asthma)
Either AR or AC
(no asthma)
RRR (95% CI) RRR (95% CI) RRR (95% CI) RRR (95% CI) RRR (95% CI)
Male (N = 13,299)
Non‐sensitized 1 1 1 1 1
Sensitized 2.86 (2.38–3.44) 13.8 (9.39–20.4) 82.2 (52.2–129) 42.3 (35.0–51.0) 8.58 (7.27–10.1)
No parental allergy 1 1 1 1 1
Parental allergy 1.67 (1.32–2.11) 2.69 (1.82–3.96) 3.78 (2.98–4.78) 2.77 (2.35–3.26) 2.15 (1.74–2.64)
Small municipality 1 1 1 1 1
Large municipality 1.12 (0.93–1.35) 0.96 (0.68–1.35) 0.88 (0.71–1.09) 0.98 (0.85–1.13) 1.08 (0.91–1.27)
Non obese 1 1 1 1 1
Obese 1.47 (1.15–1.88) 1.33 (0.83–2.12) 1.30 (0.96–1.77) 0.86 (0.69–1.06) 1.14 (0.90–1.45)
Never smoker 1 1 1 1 1
Current smoker 1.09 (0.85–1.41) 1.05 (0.66–1.66) 0.54 (0.38–0.78) 0.63 (0.51–0.78) 0.71 (0.55–0.92)
Former smoker 1.08 (0.86–1.35) 0.92 (0.60–1.42) 0.88 (0.67–1.15) 0.86 (0.72–1.01) 0.96 (0.79–1.17)
>10 blood donations 1 1 1 1 1
1–10 blood donations 1.46 (1.17–1.82) 1.17 (0.77–1.78) 1.33 (1.02–1.73) 0.99 (0.83–1.19) 0.93 (0.74–1.18)
45 years or older 1 1 1 1 1
Age below 45 years 1.72 (1.38–2.14) 1.40 (0.94–2.08) 1.19 (0.93–1.53) 0.93 (0.80–1.08) 0.79 (0.66–0.95)
Female (N = 11,958)
Non‐sensitized 1 1 1 1 1
Sensitized 1.82 (1.47–2.27) 9.39 (6.69–13.2) 36.2 (26.5–49.4) 26.1 (22.3–30.6) 6.21 (5.23–7.38)
No parental allergy 1 1 1 1 1
Parental allergy 1.64 (1.32–2.03) 2.00 (1.36–2.92) 3.28 (2.55–4.23) 2.65 (2.25–3.12) 2.31 (1.89–2.82)
Small municipality 1 1 1 1 1
Large municipality 0.86 (0.72–1.04) 0.91 (0.64–1.29) 1.12 (0.88–1.42) 0.93 (0.80–1.07) 0.84 (0.70–1.01)
Non‐obese 1 1 1 1 1
Obese 1.41 (1.11–1.79) 2.36 (1.59–3.48) 1.35 (0.97–1.88) 1.03 (0.84–1.27) 1.05 (0.83–1.34)
Never smoker 1 1 1 1 1
Current smoker 1.37 (1.08–1.73) 1.05 (0.64–1.70) 1.10 (0.79–1.54) 0.88 (0.71–1.09) 1.12 (0.88–1.43)
Former smoker 1.02 (0.80–1.29) 1.27 (0.85–1.90) 1.24 (0.93–1.65) 1.09 (0.91–1.29) 1.11 (0.91–1.36)
>10 blood donations 1 1 1 1 1
1–10 blood donations 1.50 (1.23–1.82) 1.29 (0.88–1.88) 1.15 (0.88–1.49) 1.03 (0.87–1.22) 0.78 (0.63–0.97)
45 years or older 1 1 1 1 1
Age below 45 years 2.08 (1.64–2.63) 1.46 (0.97–2.20) 1.26 (0.94–1.68) 0.94 (0.80–1.11) 0.87 (0.72–1.06)
Notes: Results are presented as adjusted relative risk ratios (RRR) with 95% CI. One analysis for each sex adjusted for all covariates was performed.
Controls served as base. Significant results after Bonferroni correction are shown in bold. Sensitized: sIgE (Phadiatop) ≥ 0.35 kU/L. Non‐sensitized: sIgE
(Phadiatop) < 0.35 kU/L.
Abbreviations: AC, allergic conjunctivitis; AR, allergic rhinitis; ARC, both AR and AC; CI, confidence intervals; sIgE, allergen‐specific immunoglobulin E.
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4 | DISCUSSION
In this cohort of Danish blood donors, the prevalence of AR, AC,
asthma, and inhalant allergen sensitization was 19%, 15%, 9%, and
30%, respectively. The prevalence of inhalant allergen sensitization,
allergic asthma, non‐allergic asthma, and ARC increased over time
and the youngest birth cohorts experienced asthma symptoms at an
earlier age. Moreover, inhalant allergen sensitization and allergic
predisposition increased the risk of the diseases. Allergic multi-
morbidity was associated with inhalant allergen sensitization and
participants with ARC had a higher sIgE seroprevalence than par-
ticipants with either AR or AC, indicating that self‐reported ARC
represent a primarily sIgE‐positive phenotype, while those with
either AR or AC represent a more diverse phenotypes. Farm
upbringing had a protective effect on acquiring ARC but only in
inhalant allergen sensitized participants. Inhalant allergen sensitiza-
tion was associated with male sex, allergic predisposition, and age
younger than 45 years. As expected seasonal AR was frequently
accompanied by AC.32
Among participants younger than 45 years, the prevalence of AR
was 20.9%, 95% CI: 20.5%–21.4%, thus slightly lower than in a
previous Danish study (23.5%, 95% CI: 22.5%–24.5%)1 and in the
RHINE study (24.0%, 95% CI: 23.2%–24.6%)2 that are based on the
same ECRHS questions in individuals aged 20–44 years. However,
the prevalence of asthma of 11.2%, 95% CI: 10.9%–11.6% was
similar to the previous Danish study (11.3%, 95% CI: 10.6%–12.0%),1
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F I GUR E 2 Risk of allergic rhinitis (AR), allergic conjunctivitis (AC), and asthma in relation to geographical upbringing. Multinomial logistic
regression analysis adjusted for sex, age, smoking behavior, parental allergy, body mass index, total number of blood donations, and current
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The lower disease prevalence in participants aged 45 or older
may be related to the lower prevalence of the risk factors, for
example, inhalant allergen sensitization and allergic predisposition,
as well as the healthy donor effect.33–35 Few studies have examined
the age effect on the coexistence of asthma and allergic diseases.
Similar to other studies, our results showed increased risk of expe-
riencing asthma, AR, or AC symptoms, in the youngest compared
with the oldest birth cohort for participants with ARC and allergic
asthma. However, contrary to other studies, this was also seen for
asthma only.36 In this study, we assessed both temporal and age‐
related changes. Changes in symptoms and diseases may be related
to changes in life style,37 microbial exposure in the environment,38
and changes in healthcare patterns, for example, changes in
perception of illness and diagnostic practices over time.
A diverse and mature microbiota lowers the prevalence of
atopy.39–42 Hence, the urbanization categories were used as proxy
measures for microbial load and diversity early in life.1 Consistent
with previous studies, growing up on farms (an environment rich in
microbial load) was associated with lower risk of allergic sensitiza-
tion, AR, and allergic asthma in adulthood.2,10 Asthma, AR, and AC
often coexist in the same individuals (multimorbidity). When strati-
fying our study population into two allergic groups, we found that
farm childhood only had a protective effect on acquiring ARC
(allergic multimorbidity) with and without asthma and not on
acquiring either AR or AC. Combining self‐reported data with data
on inhalant allergen sensitization showed that the effect was only
present in sensitized participants with ARC. We speculate that the
protective effect of farm childhood on allergic disease in adulthood is
explained by the protective effect on allergic sensitization which
strongly correlates with ARC.
We further speculate that the parental allergy factor may also
impact the results. A Swedish study showed that men with allergy
more often chose to move from farms compared to those without
allergy, resulting in a healthy worker effect with less atopy and less
severe symptoms in the farming population.43 In our study popula-
tion, parental allergy was less frequent in participants from farms
compared to participants from inner city and most of the participants
from inner cities were currently residents in a large municipality
(with higher exposure to air pollution). Nevertheless, adjusting for
parental allergy and current municipality residence only slightly
altered the results. Use of self‐reported exposures and outcomes, in
particular dating back to early life, may induce recall bias. However,
we expect that participants were able to remember place of up-
bringing with a reasonable accuracy.
An association between obesity and asthma, especially, in fe-
males may exist. Though, the causality between obesity and asthma is
still uncertain; a suggested explanation is due to changes in systemic
metabolism.15,44,45
The overall seroprevalence of inhalant allergen sensitization was
30% which is consistent with other studies.9,10 As expected, inhalant
allergen sensitization was positively associated with male sex, allergic
predisposition, and younger age,11,46,47 while current and former
TAB L E 4 Multivariable logistic




Crude OR (95% CI) Adjusted OR (95% CI)
Female (reference) 1 1
Male 1.53 (1.45–1.61) 1.57 (1.49–1.67)
No parental allergy (reference) 1 1
Parental allergy 2.34 (2.19–2.51) 2.22 (2.08–2.39)
Small municipality (reference) 1 1
Large municipality 1.27 (1.21–1.35) 1.12 (1.06–1.19)
Non obese (reference) 1 1
Obesity 0.89 (0.82–0.97) 0.95 (0.87–1.03)
Never smoker (reference) 1 1
Current smoker 0.86 (0.79–0.93) 0.87 (0.80–0.95)
Former smoker 0.77 (0.72–0.82) 0.85 (0.79–0.91)
>10 blood donations (reference) 1 1
1–10 blood donations 1.16 (1.08–1.24) 0.99 (0.92–1.06)
45 years or older (reference) 1 1
Age below 45 years 1.54 (1.45–1.63) 1.33 (1.25–1.42)
Note: Results are presented as OR with 95% CI. Crude: univariate logistic regression without
adjustment. Adjusted: adjustment for sex, parental allergy, municipality, obesity, smoking behavior,
total number of blood donations, and age. Significant results after Bonferroni correction are shown
in bold. Sensitized: sIgE (Phadiatop) ≥ 0.35 kU/L.
Abbreviations: CI, confidence intervals; OR, odds ratios; sIgE, allergen‐specific immunoglobulin E.
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smoking had a protective effect.48 The overall sensitivity of the
Phadiatop analysis was 91% among participants with both ARC and
asthma. This is in accordance with other studies showing that poly-
sensitization is higher in individuals with allergic multimorbidity than
in those with single diseases.49–51 The Phadiatop analysis includes
allergens from the nine most common respiratory sensitizers, but the
participants could be sensitized to other allergens, have local AR,52 or
they could represent a non‐allergic phenotype.
We found a strong association between allergic multimorbidity
and asthma. It is, however, a limitation of our study that severe
asthmatic individuals are not included. Allergic multimorbidity is
tightly associated with severe asthma.53–56 The absence of partici-
pants with severe asthma in our study population could cause un-
derestimation of the prevalence of asthma with allergic
multimorbidity (AR and AC) and explain why only 47% of our asth-
matic participants have concomitant AR, while this proportion is
64.5% in another study using the ECRHS cohort.57
The strength of our study is a large, overall healthy, and well‐
characterized study population. We included a detailed standardized
questionnaire and an objective marker of allergic sensitization. The
DBDS relies on the existing infrastructure of continuous collection of
blood samples in the Danish blood centers and on the local staff at the
blood centers, who collect questionnaire data during blood donation.
The participation rate was high,24 and the number of unanswered
questions in thequestionnaire is low (approximately 3%). Prior to study
inclusion, the questions were unknown to the blood donors. All par-
ticipants in our studywereunremunerated voluntary blooddonors and
had no incentive to non‐disclosure of diseases. Although the cross‐
sectional design hinders causal inference, it allows exploration of as-
sociations to generate hypotheses for further research.
5 | CONCLUSION
Birth year, childhood residence, inhalant allergen sensitization, and
allergic predisposition had an effect on the risk of asthma, AR, and AC.
We found that individuals with self‐reported ARC represent a pri-
marily sIgE phenotype while those with either AR or AC represent
more diverse phenotypes, and we suggest that the two phenotypes
are analyzed separately in epidemiological studies based on only self‐
reported allergy.
The DBDS blood donor population proves well‐suited for further
studies of gene–environment interactions and biomarkers related to
airborne allergy and asthma.
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AP P END I C E S
Q u e s t i o n n a i r e
Questions Definition
“Do you have any nasal allergies including hay fever?” Allergic rhinitis (AR)
In addition an affirmative answer to:
“In which months of the year do this nose problem occur?” Months with nasal symptoms
“How old were you when you first had hay fever or nasal allergy?” First nasal symptoms
“When were the last time you had nasal symptoms?” Last nasal symptoms
“Have you ever had a problem with sneezing, or a runny or a blocked nose when you did
not have a cold or the flu?”
Nasal symptoms
“Do you have any eye allergies including hay fever?” Allergic conjunctivitis (AC)
In addition an affirmative answer to:
“In which months of the year do this eye problem occur?” Months with eye symptoms
“How old were you when you first had hay fever or eye allergy?” First eye symptoms
“When were the last time you had eye symptoms?” Last eye symptoms
“Have you ever had a problem with itchy or watery eyes?” Eye symptoms
“Do you have any nasal allergies including hay fever?” AND “Do you have any eye allergies
including hay fever?”
Allergic rhino‐conjunctivitis (ARC)
“Do you have or have you ever had asthma?” Asthma
In addition an affirmative answer to:
“Have you ever had asthma diagnosed by a doctor?” Doctor‐diagnosed asthma
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Qu e s t i o n n a i r e (Continued)
Questions Definition
“Which months of the year do you usually have trouble with your breathing?” Months with asthma symptoms
“How old were you when you had your first attack of asthma?” First asthma symptom
At least one of the following:“Are you currently taking any medicine (including inhalers,
aerosols or tablets) for asthma?”“Have you been woken by an attack of coughing at
any time in the last 12 months?”“Have you been woken by an attack of shortness of
breath at any time in the last 12 months?”“When were the last time you had an attack
of asthma?” – With the answer “Within the last 12 month”.
Current asthma
“Have you had wheezing or whistling in your chest at any time?” and “Have you been at all
breathless when the wheezing noise was present?”
Respiratory symptoms
No AR, no AC, and no asthma Controls
“Have one or both of you parents allergy?” Allergic predisposition
“Which category best describes the place you lived most of the time when you were under
the age of five years?”1) a farm with livestock, 2) a farm without livestock, 3) a village in
a rural area, 4) a small town, 5) a suburb of city, or 6) inner city of Copenhagen, Aarhus,
Odense, Aalborg, or Esbjerg*
Place of upbringing
Current smoking: “Do you smoke?”. Former smoking: “Have you smoked earlier?”. Never
smoking: negative answers to the two questions. Smokers stated the duration of
smoking (years) and the year of smoking cessation.
Smoking behavior
“How much do you weigh?” Weight
“How tall are you?” Height
Note: Body mass index (BMI) (kg/m2) was calculated from self‐reported weight and height and obesity was defined as a BMI ≥ 30 kg/m2.
*The five largest cities in Denmark with 72,000 to 727,000 citizens.
F I GUR E A 1 Distribution of phenotypes. Distribution of self‐
reported allergic rhinitis (AR), allergic conjunctivitis (AC), asthma,
and the six phenotype groups in the overall study population.
Irrespective of sex. Controls: no AR, no AC, and no asthma. Results
are presented as numbers. In total 862 (1.6%) could not be
categorized due to missing data in self‐reported AR, AC, or asthma
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TAB L E A2 Association between allergic rhino‐conjunctivitis, asthma, and inhalant allergen sensitization (N = 25,257)
Self‐reported diseases and symptoms Sex
Total Sensitized
N N (%)
AR (no AC and no asthma) Female 470 231 (49.1)
Male 593 392 (66.1)
AC (no AR and no asthma) Female 168 77 (45.8)
Male 149 105 (70.5)
ARC (no asthma) Female 1210 972 (80.3)
Male 1489 1357 (91.1)
Asthma, and either AR or AC Female 148 89 (60.1)
Male 154 120 (77.9)
Asthma and ARC Female 344 294 (85.5)
Male 441 420 (95.2)
Asthma (no AR, no AC) Female 524 119 (22.7)
Male 531 223 (42.0)
No asthma, no AR, and no AC With nasal‐, eye‐, or respiratory symptoms Female 2571 453 (17.6)
Male 2650 641 (24.2)
No asthma, no AR, and no AC Without nasal‐, eye‐, and respiratory symptoms Female 6303 711 (11.3)
Male 7057 1169 (16.6)
Totala Female 11,958 2994 (25.0)
Male 13,299 4491 (33.8)
Note: Results are presented as numbers and percentages.
Abbreviations: AR, allergic rhinitis; AR, allergic conjunctivitis; ARC: both AR and AC; Sensitized: allergen‐specific immunoglobulin E (Phadiatop) ≥ 0.35
kU/l.
aTotal does not sum up the numbers above due to missing data in one of the variables asthma, AR or AC (N = 455)
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TAB L E A4 Characteristics of the study population stratified by inhalant allergen sensitization (N = 25,257)
N (%) Non‐sensitized Sensitized Comparison
17,772 (70.4) 7485 (29.6)
Sex Median (IQR) Median (IQR)
Age F 40.9 (27.7–51.9) 37.3 (26.3–48.3) **
M 43.1 (31.4–53.2) 38.6 (28.8–48.8) **
BMI F 24.4 (22.1–27.6) 24.2 (22.0–27.3) NS
M 25.5 (23.6–27.8) 25.3 (23.4–27.8) *
Sex % (95% CI)a % (95% CI)a
Females ‐ 50.4 (49.7–51.2) 40.0 (38.9–41.1) **
Current smokers F 14.6 (13.8–15.3) 13.4 (12.2–14.6) NS
M 12.9 (12.3–13.7) 12.4 (11.5–13.5) NS
Former smokers F 24.1 (23.2–25.0) 21.0 (19.6–22.5) *
M 23.5 (22.6–24.4) 19.1 (17.9–20.2) **
Large municipality F 37.9 (36.9–38.9) 41.9 (40.2–43.7) *
M 34.8 (33.8–35.8) 42.2 (40.8–43.7) **
Obesity F 14.3 (13.6–15.0) 13.2 (12.1–14.5) NS
M 12.6 (11.9–13.3) 11.4 (10.5–12.4) NS
Parental allergy F 16.1 (15.4–16.9) 29.6 (28.0–31.2) **
M 11.3 (10.6–11.9) 23.2 (22.0–24.5) **
N % (95% CI)b % (95% CI)b
Age strata (years) **
18–24 3493 66.6 (65.0–68.1) 33.4 (31.9–35.0)
25–34 6040 66.5 (65.3–67.7) 33.5 (32.3–34.7)
35–44 5531 67.4 (66.1–68.6) 32.6 (31.4–33.9)
45–54 5873 73.1 (72.0–74.2) 26.9 (25.8–28.0)
55–67 4320 78.9 (77.7–80.1) 21.1 (19.9–22.3)
Region **
Capital Region of Denmark 7627 66.7 (65.6–67.7) 33.3 (32.3–34.4)
Central Denmark Region 8524 70.8 (69.8–71.8) 29.2 (28.2–30.2)
Zealand Region of Denmark 4851 73.4 (72.1–74.6) 26.6 (25.4–27.9)
North Denmark Region 4255 72.7 (71.3–74.0) 27.3 (26.0–28.7)
Place of upbringing **
Farm with livestock 3871 78.8 (77.4–80.0) 21.3 (20.0–22.6)
Farm without livestock 594 69.4 (65.5–72.9) 30.6 (27.1–34.5)
Rural area 4698 71.3 (70.0–72.6) 28.7 (27.4–30.0)
Small town 8222 69.0 (68.0–70.0) 31.0 (30.0–32.0)
Suburb 4938 66.8 (65.4–68.1) 33.2 (31.9–34.6)
Inner city 2842 67.4 (65.6–69.1) 32.6 (30.9–34.4)
Months with nasal or eye symptoms in participants with ARC
April–August 2330 9.53 (8.40–10.8) 90.5 (89.2–91.6) **
September–March 40 20.0 (10.5–34.8) 80.0 (65.2–89.5)
Always 858 18.9 (16.4–21.6) 81.1 (78.4–83.6)
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T A B L E A 4 (Continued)
Sex % (95% CI)a % (95% CI)a
Age at first nasal or eye symptom in participants with ARC (years)
Before 10 934 6.75 (5.77–9.37) 93.3 (91.5–94.7) **
10–30 2103 12.0 (10.7–13.7) 88.0 (86.6–89.3)
31–50 421 27.1 (22.7–31.8) 72.9 (68.5–76.9)
After 50 29 48.3 (30.0–66.5) 51.7 (34.4–68.6)
Time since last nasal or eye symptoms in participants withARC
1 year or less 3066 12.1 (11.0–13.3) 87.9 (86.7–89.0) NS
More than 1 year 422 17.1 (13.8–20.9) 82.9 (79.1–86.2)
Notes: Results are presented as percentages with corresponding 95% confidence intervals (CI) and medians with interquartile ranges (IQR). Groups were
compared by Kruskall‐Wallis test for non‐normally distributed data, and chi‐squared test for categorical data whenever all estimated counts were >5,
and a 105‐fold Monte Carlo simulated estimate for Fisher's exact test whenever estimated counts were ≤ 5. P‐values were Bonferroni corrected,
*p < 0.05; **p < 0.001; NS: non‐significant.
Abbreviations: ARC, allergic rhinitis (AR) and allergic conjunctivitis (AC); F, female; M, male; non‐sensitized, allergen‐specific immunoglobulin E
(Phadiatop) <0.35 kU/L; sensitized, allergen‐specific immunoglobulin E (Phadiatop) ≥ 0.35 kU/L.
aCompared with the total number of participants in the column. bCompared with the total number of participants in the row.
F I GUR E A 2 Cumulative incidence proportions in each of the birth cohorts. Cumulative incidence proportions (and corresponding 95%
confidence intervals) of self‐reported asthma, allergic rhinitis (AR), and allergic conjunctivitis (AC) by age in ten‐year birth cohorts in the
overall study population, irrespective of sex. Participants can appear in more than one symptom group
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F I GUR E A 3 ROC curve analysis.
Association between different Phadiatop cutoff
values and self‐reported allergic rhinitis and
allergic conjunctivitis (ARC) analyzed by
receiver operating characteristic (ROC) curve
with reported area under the curve (AUC)
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F I GUR E A 4 Months with symptoms of allergy and/or asthma. Nasal‐, eye‐ or asthma symptoms in participants with allergic rhinitis (AR),
allergic conjunctivitis (AC), and asthma (n = 6278) stratified by inhalant allergen sensitization. Results are presented as proportions of the
allergic and/or asthmatic participants. The figure shows both sexes in one. Participants could give more than one answer and appear in more
than one symptom group
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